Current Safety of Renal Allograft Biopsy With Indication in Adult Recipients

An Observational Study

Shang-Feng Tsai, MD, Cheng-Hsu Chen, PhD, Kuo-Hsiung Shu, MD, Chi-Hung Cheng, PhD, Tung-Min Yu, PhD, Ya-Wen Chuang, Shih-Ting Huang, Jun-Li Tsai, MD, and Ming-Ju Wu, PhD

Abstract: Renal biopsy remains the golden standard diagnosis of renal function deterioration. The safety in native kidney biopsy is well defined. However, it is a different story in allograft kidney biopsy. We conduct this retrospective study to clarify the safety of allograft kidney biopsy with indication.

All variables were grouped by the year of biopsy and they were compared by Mann–Whitney U test (for continuous variables) or Chi-square test (for categorical variables). We collected possible factors associated with complications, including age, gender, body weight, renal function, cause of uremia, status of coagulation, hepatitis, size of needle, and immunosuppressants.

We recruited all renal transplant recipients undergoing allograft biopsy between January of 2009 and December of 2014. This is the largest database for allograft kidney biopsy with indication. Of all the 269 biopsies, there was no difference in occurrence among the total 14 complications (5.2%) over these 6 years. There were only 3 cases of hematomas (1.11%), 6 gross hematuria (2.23%), 1 hydronephrosis (0.37%), and 2 hemoglobin decline (0.74%). The outcome of this cohort is the best compared to all other studies, and it is even better than the allograft protocol kidney biopsy. Among all possible factors, patients with pathological report containing “medullary tissue only” were susceptible to complications ($P < 0.001$, 1.8 of relative risk).

In modern era, this study demonstrates the safety of allograft kidney biopsy with indication. Identifying the renal capsule before biopsy to avoid puncture into medulla is the most important element to prevent complications.

 INTRODUCTION

Renal biopsy remains the gold standard for diagnosis of renal function deterioration, including native and allograft kidney. In addition to diagnosis, pathological data can provide nephrologists with useful information regarding disease severity, activity, and chronicity, which can be used to guide treatment. Renal biopsy has been widely used in clinical practice for more than 100 years. This procedure is considered to be safe with acceptable complications. Percutaneous biopsy was introduced in the 1940s, and ultrasound-guided biopsy has been used since the 1960s. During the late 1980s, manual needles were gradually replaced by automated spring-loaded biopsy device, which made renal biopsy much safer and thus rapidly found wide acceptance by clinicians. The safety and complications in native kidney biopsy were established in a systematic review and meta-analysis, which included 36 studies conducted after 1990. However, the complications were highly dependent on techniques and protocols in different countries. Even in a study using data from a database of a single country, the Norwegian Kidney Biopsy Registry (1988–2010), a number of factors were still affected by the different protocols and techniques used. Percutaneous biopsy in native kidneys is thought to be a low-risk procedure without major complications. However, the risks and complications associated with allograft kidney biopsy are less well understood and should be clarified for the following reasons. First, organ shortage is a common problem worldwide, so there are relatively few studies which include data on allograft kidney biopsy. Second, recipients only have a solitary functioning kidney with less well preserved renal function. Third, studies on allograft kidney biopsy mostly date back 25 years and there are scant data from recent studies. Progress in biopsy safety was made with the introduction of the automated spring-loaded biopsy device and ultrasound guidance. The rate of complications varied according to different eras. In the past 10 years, no studies with large case numbers have been conducted to investigate allograft kidney biopsy. Fourth, the safety of allograft biopsy in children and adolescents was investigated by Franke et al., but adults were not included in the study. Finally, in the past 15 years, the largest study on adult allograft kidney biopsy was published in 2003, and reported on the safety of “protocol” biopsy in allograft kidney, rather than “indication” biopsy in...
allograft kidney. There are considered to be fewer complications associated with protocol biopsy than with indication biopsy because biopsy for allograft kidneys in normal situation (protocol biopsy) is safer than in problematic kidney (biopsy with indication). However, there is currently no evidence to prove this. Therefore, we conducted this retrospective study to clarify the safety of adult allograft kidney biopsy with indication in the modern era and to identify any risk factors.

**SUBJECTS AND METHODS**

**Study Population**

Kidney biopsy is encouraged for patients with unexplained proteinuria or renal function deterioration in Taichung Veterans General Hospital. We recruited all renal transplant recipients who underwent “allograft” biopsy between January of 2009 and December of 2014. All subjects in this study were 20 years of age or older. Patients were free from infectious disease, inflammatory disease, liver disease, or malignancy, and all were nonsmokers. All of the study procedures were conducted in accordance with the ethical standards of Taichung Veterans General Hospital and were approved by the institutional review committee (CE14172, Taichung Veterans General Hospital). It was approved after expedited review procedures in Taichung Veterans General Hospital.

**Data Collection**

We collected the participants’ clinical parameters including gender, age (years), body weight (kg), timing of kidney biopsy (months after transplantation), cause of end-stage renal disease, and living donor or cadaveric donor. All diabetes mellitus (DM) patients were diagnosed according to the DM guidelines of the American Diabetes Association in 2013. Hypertension was defined as an average home systolic blood pressure greater than 140 mm Hg and a diastolic blood pressure greater than 90 mm Hg before medication, according to the definition for stage 1/II hypertension set forth in the JNC-7 guidelines. Hepatitis B or C infections were confirmed by medical records, which were examined before transplantation in all recipients. Serum data were collected, serum creatinine (SCr) (mg/dL), estimated glomerular filtrate rate (eGFR) (mL/min per 1.73 m²), hemoglobin (g/dL), platelet (/, u/L), prothrombin time, and activated partial thromboplastin time (seconds). The index eGFR was calculated using the modification of diet in renal disease equation:

\[
eGFR = 186 \times \frac{SCr^{−1.154}} \]

\* Age −0.203 + 0.742 (if female). PCR was defined by spot urine test ratio of protein and creatinine (mg/g). Immunosuppressants were defined if any drug was used for at least 3 months before renal biopsy. Postbiopsy urinary tract infection was defined as symptoms of frequency, urgency, or pyuria in recipients. Hematoma, hydrenephrosis, and arteriovenous fistula were detected by ultrasound. Deep biopsy to the medulla was defined according to the results of the pathological report. Also, the diagnosis of allograft biopsy and number of glomeruli were also performed according to the pathological report.

**Biopsy Protocol**

Allograft kidney biopsy protocol is frequently performed in Taichung Veterans General Hospital in all recipients with unexplained proteinuria or elevation of SCR. All patients were admitted for graft kidney biopsy. Before biopsy, recipients should control systolic blood pressure below 180 mm Hg. Antiplatelet or antithrombotic agents (eg, aspirin, omega-3 fatty acids, GP IIb/IIIa inhibitors, dipyridamole, and nonsteroidal antiinflammatory drugs) should be discontinued at least 7 days before biopsy, and warfarin should be discontinued at least 3 days before biopsy or the prothrombin time should be normalized. Pentoxifylline cannot be taken within 1 day before biopsy. Patients are instructed not to take the abovementioned drugs 7 days after biopsy. One day before biopsy, platelet, prothrombin time, and activated partial thromboplastin time should be normal. Biopsy is not performed in patients with SBP more than 180 mm Hg or abnormal coagulation function. It is important to note that Desmopressin 4 unit is infused 30 minutes before biopsy in all patients. All biopsies were performed by real-time ultrasound guidance by nephrologists. Before biopsy, the skin overlying the biopsy site should be free of signs of infection. The patient should also be able to comply with simple directions (such as holding breath for at least 5 seconds). Under ultrasound guidance (3.5 MHz transducer with real-time visualization of the needle), a spinal needle was used to locate the capsule of the upper pole and to provide anesthesia for the biopsy needle tract. Two cores of renal tissue measuring 1 cm in length were generally recommended. We used an automated spring-loaded biopsy device (Bard Max-Core Disposable Core Biopsy Instrument) and the size of needle used varied between 16 and 18 G. Immediately after biopsy, we checked for any bleeding, hematoma, or arteriovenous fistula by ultrasound. All patients were required to rest in bed for at least 2 hours post-biopsy. Patients were instructed to maintain a supine posture in bed for 2 hours, and bed rest overnight was further recommended. The duration of the procedure was typically 23 minutes. To help detect bleeding and other complications, vital signs were closely monitored within 6 hours after biopsy. Blood pressure were controlled as well as possible (goal <140/90 mm Hg). If any gross hematuria, back or abdominal pain, or dizziness or nausea were noted, urinalysis, hemoglobin, and serum sodium examinations were conducted. Ultrasound was also done to detect any complications. All patients received ultrasound regularly 1 day after biopsy without exception. That is to say, patients were under observation for at least 24 hours after biopsy. All patients were followed up to check for any complications for at least 1 year after biopsy. Complications (hematoma, hematuria, hydrenephrosis, arteriovenous fistula, blood transfusion, hemoglobin decline, angiographic intervention to control bleeding, nephrectomy to control bleeding, and death) and any treatments were all recorded.

**Statistical Methods**

Data are expressed as mean ± standard deviation for continuous variables and as frequency/percent for categorical variables. Demographic and clinical characteristics of the entire cohort were recorded according to years. The basic characteristics of recipients and complications divided by year of biopsy were compared by Mann–Whitney U test (for continuous variables) or Chi-square test (for categorical variables). Univariate logistic regression model was used to analyze the possible factors associated with complications after renal biopsy. A P value <0.05 was considered statistically significant. All statistical procedures were performed using the SPSS statistical software package, version 17.0 (Chicago, IL).

**RESULTS**

All 1563 biopsies were selected, of which 269 allograft biopsies were selected for analysis. All basic parameters of this cohort are summarized in Table 1. The adult recipients’ cohort had a mean age of 50.3 years old and 49.4% were male. Renal functions were poor (4.02 ± 3.20 mg/dL of SCr,
TABLE 1. Basic Characteristics of Recipients Receiving Allograft Kidney Biopsy According to Years

| Year | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | P Value | Total |
|------|------|------|------|------|------|------|---------|-------|
| Year | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | P Value | Total |
| Value | Total |
| Graft biopsy/all biopsy, % | 34/441 (7.7%) | 40/263 (15.2%) | 31/176 (17.6%) | 48/206 (23.3%) | 45/225 (20%) | 71/252 (25.2%) | 0.630 | 269/1563 (17.2%) |
| Gender (M) (n, %) | 20 (58.8%) | 21 (52.5%) | 10 (32.3%) | 22 (45.8%) | 21 (46.7%) | 39 (54.9%) | 0.285 | 133 (49.4%) |
| Age, y/o | 48.4±14.0 | 46.9±11.6 | 52.6±11.8 | 52.3±11.7 | 50.4±16.4 | 50.6±11.4 | 0.280 | 50.3±12.8 |
| Creatinine, mg/dL | 4.33±3.26 | 4.26±3.70 | 3.28±2.59 | 4.29±3.22 | 3.80±3.45 | 4.02±3.00 | 0.862 | 4.02±3.20 |
| GFR, mL/min/1.732 m² | 24.64±15.41 | 26.36±16.21 | 26.16±11.14 | 26.01±16.41 | 27.14±12.26 | 25.84±15.48 | 0.994 | 26.04±14.71 |
| PCR | 3.98±6.48 | 7.49±9.76 | 11.39±14.28 | 5.05±7.71 | 8.86±11.67 | 6.16±9.47 | 0.067 | 6.96±10.19 |
| Timing of biopsies, months | 23.1±20.8 | 40.2±16.3 | 35.5±19.9 | 26.6±20.5 | 42.4±16.3 | 28.5±19.9 | <0.0001 | 32.3±20.1 |
| Cause of uremia | | | | | | | | |
| DM (n, %) | 13, 38.8% | 16, 40% | 10, 32.3% | 16, 33.3% | 28, 39.4% | 0.632 | 100, 37.2% |
| Hypertension (n, %) | 6, 17.6% | 8, 20% | 7, 22.6% | 9, 18.8% | 9, 20% | 15, 21.1% | 0.236 | 54, 20.2% |
| Others (n, %) | 10, 29.4% | 9, 22.5% | 7, 22.6% | 13, 27.1% | 9, 20% | 14, 19.7% | 0.260 | 54, 20.2% |
| SBP, mmHg | 132.3±18.2 | 138.9±15.2 | 139.0±16.1 | 136.4±16.7 | 137.5±16.1 | 131.6±16.6 | 0.423 | 137.2±16.4 |
| Graft kidney size, mm | 114.6±8.2 | 113.0±9.3 | 108.2±21.0 | 114.5±8.3 | 109.3±17.9 | 113.4±9.1 | 0.263 | 112.4±12.7 |
| Hemoglobin, g/dL | 9.94±1.94 | 10.24±2.14 | 9.96±2.01 | 10.25±2.13 | 10.12±2.07 | 10.13±2.07 | 0.978 | 10.12±2.05 |
| Platelet, /µL | 188117.6±60918.6 | 190150.0±60207.2 | 192096.8±61781.5 | 189500.0±61563.3 | 189889.9±60977.7 | 188662.0±60246.1 | 1.000 | 189565.1±60285.7 |
| PT | 10.2±1.2 | 10.1±1.3 | 10.0±2.0 | 10.2±1.9 | 10.6±1.0 | 10.9±1.3 | 0.853 | 10.3±0.9 |
| aPTT | 24.3±2.3 | 25.3±3.3 | 25.1±2.9 | 24.9±2.3 | 25.2±2.9 | 24.9±3.0 | 0.293 | 25.1±3.3 |
| Hepatitis B (n, %) | 8, 23.5% | 5, 12.5% | 4, 12.9% | 7, 14.6% | 6, 13.3% | 8, 11.3% | 0.132 | 38, 14.1% |
| Hepatitis C (n, %) | 4, 11.8% | 5, 12.5% | 3, 9.7% | 6, 12.5% | 4, 8.9% | 11, 15.5% | 0.236 | 33, 12.3% |
| Living donor (n, %) | 10, 29.4% | 9, 22.5% | 11, 35.5% | 15, 31.3% | 12, 26.7% | 22, 31.0% | 0.269 | 79, 29.4% |
| 16-gauge needle (n, %) | 17, 50.0% | 30, 75.0% | 18, 58.1% | 30, 62.5% | 30, 66.7% | 40, 56.3% | 0.963 | 165, 61.3% |
| Body weight, kg | 64.8±13.3 | 62.5±12.4 | 62.9±13.0 | 65.0±14.0 | 61.4±12.4 | 63.7±12.8 | 0.623 | 63.4±13.0 |
| Immunosuppressant | | | | | | | | |
| Prednisolone | 33, 97.1% | 36, 92.3% | 26, 86.7% | 45, 95.7% | 38, 86.4% | 66, 94.3% | 0.322 | 244, 92.4% |
| Tacrolimus | 32, 94.1% | 32, 82.1% | 25, 83.3% | 41, 87.2% | 36, 81.8% | 62, 88.6% | 0.599 | 228, 86.4% |
| Cyclosporin | 2, 5.9% | 7, 17.9% | 2, 6.7% | 4, 8.5% | 5, 11.3% | 7, 10% | 0.5752 | 27, 10.2% |
| Mycopholic | 15, 44.1% | 16, 41.0% | 13, 43.3% | 20, 41.7% | 20, 46.5% | 30, 42.3% | 0.997 | 114, 43.0% |
| Cellcept | 15, 44.1% | 16, 41.0% | 10, 33.3% | 16, 34.0% | 19, 42.2% | 25, 36.2% | 0.890 | 101, 38.3% |
| mTOR inhibitor | 8, 23.5% | 10, 25.0% | 7, 22.6% | 10, 20.8% | 12, 26.7% | 18, 25.4% | 0.653 | 65, 24.2% |

aPTT = activated partial thromboplastin time, DM = diabetes mellitus, GFR = glomerular filtration rate, GN = glomerulonephrophy, PCR = protein creatinine ration, PT = prothrombin time, SBP = systolic blood pressure.
26.04 ± 14.71 mL/min 1.732 m² of GFR, and 6.96 ± 10.19 of PCR) because of “indication” biopsy. The timing of allograft biopsy was variable because of “indication” rather than “protocol” biopsy. Most recipients (36.8%) received renal replacement therapy due to DM and were with well-controlled hemoglobin (12.7 mm). Before biopsy, as mentioned in biopsy protocol, we made sure the normal coagulation functions were necessary. In total, complications comprised only 3 cases (5.2%) (Table 2). There were no statistically significant differences in all complications in the 6-year study period. The total complication rates remained unchanged during the study period (P = 0.236). In 2010, 2 recipients had hematoma (2.56%), 6 gross hematuria (2.23%), 1 hydronephrosis (0.37%), and 2 hemoglobin decline (0.74%). No patient needed Desmopressin (0.74%). No arteriovenous fistula, graft loss, or patient death was noted and no patients needed angiographic invention or nephrectomy to stop bleeding. Recipients with or without complications were analyzed in Table 3. Of all the potential factors, a pathological report noting “medullary tissue only” was a risk factor for postbiopsy complications (P < 0.001, 1.8 of relative risk) by univariate logistic regression. Other recipient conditions or biopsy-related factors did not appear to affect the risk of postbiopsy complications.

**DISCUSSION**

Renal biopsy is the final diagnosis for kidney disease, including native and allograft kidneys. It is an essential tool for diagnosis and treatment, especially in cases of renal transplantation. The safety and complications in native kidney biopsy have been well defined. However, studies on allograft kidney biopsy are still lacking. The largest study on allograft kidney biopsy was conducted in 2003, which included 2127 cases. The study reported that the incidence of clinically significant complications after protocol biopsy of a stable renal transplant was low. However, the study was conducted than 10 years ago and all of the studied cases were protocol allograft kidney biopsy. Recently, but also already 10 years ago, a study with transplant protocol biopsies was done and there were 508 patients. Patients receiving protocol biopsy are more stable than patients receiving biopsy with indication. Biopsy with indication was always performed due to renal function deterioration or proteinuria. The association between renal dysfunction and bleeding was observed more than 200 years ago and the causes are believed to be multifactorial, including defects intrinsic to the platelet and abnormal platelet-endothelial interaction. That is, the complication rate following allograft biopsy with indication can be expected to be greater than that following protocol allograft biopsy. Moreover, most centers performed allograft kidney biopsy with indication, rather than protocol kidney biopsy.

| TABLE 2. Complications and Treatments of Allograft Kidney Biopsy According to Years |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Year            | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | P Value | Total |
| Graft biopsy    |      |      |      |      |      |      |         |      |
| Complications   |      |      |      |      |      |      |         |      |
| Infection       | 0    | 0    | 0    | 0    | 0    | 1,000| 0       | 0    |
| Hematoma (n, %) | 0    | 2    | 2,56%| 0    | 0    | 1    | 1.41%   | 0.200| 3    | 1.11% |
| Gross hematuria (n, %) | 0 | 2    | 5.0% | 0    | 0    | 4    | 2.9%   | 0.119| 6    | 2.23% |
| Hydronephrosis (n, %) | 0 | 1    | 2.5% | 0    | 0    | 0    | 0.334  | 1    | 0.37% |
| Symptomatic hyponatremia | 0 | 0    | 0    | 0    | 0    | 0    | 0       | 1    | 0    |
| Arteriovenous fistula | 0 | 0    | 0    | 0    | 0    | 0    | 1       | 0    |      |
| Hemoglobin decline | 0 | 0    | 0    | 0    | 2    | 2.82%| 0.230  | 2    | 0.74% |
| Graft loss      | 0    | 0    | 0    | 0    | 0    | 0    | 1       | 0    |      |
| Death           | 0    | 0    | 0    | 0    | 0    | 0    | 1       | 0    |      |
| Total complication (n, %) | 0 | 5    | 12.5%| 0    | 0    | 9    | 12.7%  | 0.236| 14   | 5.20% |
| Treatment       |      |      |      |      |      |      |         |      |
| Percutaneous nephrostomy | 0 | 1    | 2.5% | 0    | 0    | 0    | 0.563  | 1    | 0.37% |
| Desmopressin    | 0    | 3    | 7.5% | 0    | 0    | 5    | 7.0%   | 0.642| 8    | 2.97% |
| Blood transfusion | 0  | 2    | 2.8% | 0    | 0    | 0    | 0.266  | 0    |      |
| Angiographic intervention to control bleeding | 0 | 0    | 0    | 0    | 0    | 0    | 1       | 0    |      |
| Nephrectomy to control bleeding | 0 | 0    | 0    | 0    | 0    | 0    | 1       | 0    |      |
biopsy. Unfortunately, there are relatively few data on the safety and complications in allograft kidney biopsy with indication. Also, the complication of allograft kidney biopsy is time-dependent owing to the need for application of medical devices, including sonography to guide biopsy, automated spring-loaded biopsy device, and usage of Desmopressin. Therefore, there is a need to determine the risks and complications rates of allograft indication kidney biopsy in the modern era. A meticulous review of the recent literature within the past 10 years only described 1 study on the safety of allograft kidney biopsy.

Furthermore, the study only included children and adolescents and did not differentiate between indication and protocol biopsy. Our patient population is the largest indication allograft kidney biopsy cohort in the modern era. Consequently, the results of the present study may be of value to clinicians.

As compared to allograft ‘‘protocol’’ biopsy,9 the complications of allograft indication biopsy are as follows: hematoma (1.11% vs 2.6%), gross hematuria (2.23% vs 1.9%), arteriovenous fistula (0 vs 2.4%), graft loss (0% vs 0.04%), blood transfusion (0.74% vs 0.14%), radiological intervention (0.37% vs 0.04%), bowel perforation-related peritonitis (0 vs 0.09%), and surgical intervention (0 vs 0.09%). For the allograft indication biopsy cohort, there was a greater number of patients with gross hematuria, need for blood transfusion, and radiological intervention. Despite the higher incidence of radiological intervention in the indication allograft biopsy group, the number of such cases in both studies was just one. We believe it is very rare to require radiological intervention regardless of the type of biopsy. Much more severe complications, such as graft loss and bowel perforation, were also much lower in this indication study. In summary, we believe that even with a greater need for blood transfusion, allograft biopsy with indication did not have more severe complications than those of allograft protocol biopsy. Unexpectedly, these results showed that the risk of severe complication following a biopsy of a ‘‘normal kidney’’ was higher than that following a biopsy of an ‘‘inflamed kidney.’’ In a study by Furness et al.,9 318 patients (15.0%) were only observed for 4 hours after allograft biopsy, which we think is inadequate. In the present study, all patients were kept under observation in the hospital for at least 24 hours and followed up for up to 1 week in the outpatient department. As such, we suspect that the complication rate in the

**TABLE 3. Difference Between Recipients With or Without Complications**

| Recipients’ conditions                        | Without Complications (n = 255) | With Complications (n = 14) | P Value |
|-----------------------------------------------|--------------------------------|-----------------------------|---------|
| Gender (M) (n, %)                              | 126, 49.4%                     | 7, 50.0%                    | 0.667   |
| Age, y/o                                       | 50.3 ± 10.2                    | 49.8 ± 11.3                 | 0.511   |
| Creatinine, mg/dL                              | 4.02 ± 3.10                    | 4.01 ± 3.20                 | 0.576   |
| GFR, mL/min/1.732 m²                           | 26.10 ± 15.26                  | 25.02 ± 15.20               | 0.972   |
| PCR                                           | 6.96 ± 6.21                    | 6.90 ± 5.26                 | 0.819   |
| Posttransplant, months                         | 32.37 ± 10.3                   | 30.9 ± 11.1                 | 0.174   |
| Cause of uremia                                |                                |                             |         |
| DM (n, %)                                      | 94, 36.8%                      | 5, 35.7%                    | 0.363   |
| Hypertension (n, %)                            | 36, 14.11%                     | 6, 15%                      | 0.289   |
| GN (n, %)                                      | 37, 14.5%                      | 2, 14.3%                    | 0.246   |
| Others (n, %)                                  | 87, 34.1%                      | 4, 28.6%                    | 0.359   |
| SBP, mm Hg                                     | 137.69 ± 18.3                  | 128.2 ± 15.3                | 0.986   |
| Graf kidney size, mm                           | 112.5 ± 10.3                   | 110.2 ± 11.2                | 0.668   |
| Hemoglobin, g/dL                               | 10.17 ± 6.30                   | 9.30 ± 3.03                 | 0.290   |
| Platelet, (μL)                                 | 1907182.3 ± 30236.1            | 168561.1 ± 50253.7          | 0.076   |
| Hepatitis B (n, %)                             | 32, 12.5%                      | 2, 14.3%                    | 0.344   |
| Hepatitis C (n, %)                             | 31, 12.2%                      | 2, 14.3%                    | 0.384   |
| Body weight, kg                                | 63.6 ± 10.2                    | 59.2 ± 12.2                 | 0.615   |
| Indication due to AKI                          | 251, 98.4%                     | 12, 85.7%                   | 0.856   |
| Indication due to proteinuria                  | 183, 71.7%                     | 10, 71.4%                   | 0.748   |
| Living donor (n, %)                            | 75, 29.4%                      | 4, 28.6%                    | 0.127   |
| Immunosuppressant                              |                                |                             |         |
| Prednisolone                                   | 232, 92.8%                     | 12, 85.7%                   | 0.521   |
| Tacrolimus                                     | 216, 84.7%                     | 12, 85.7%                   | 0.147   |
| Cyclosporin                                    | 26, 10.2%                      | 1, 7.14%                    | 0.508   |
| Myfortic                                       | 109, 41.7%                     | 5, 35.7%                    | 0.301   |
| Cellcept                                       | 96, 37.6%                      | 5, 35.7%                    | 0.967   |
| mTOR inhibitor                                  | 62, 24.3%                      | 3, 21.4%                    | 0.832   |
| Biopsy-related factors                         |                                |                             |         |
| 16-gauge needle (n, %)                         | 157, 61.6%                     | 8, 57.1%                    | 0.325   |
| Second biopsy at least                         | 85, 33.3%                      | 4, 28.5%                    | 0.629   |
| Medullary tissue only                          | 8, 3.13%                      | 12, 85.7%                   | <0.001  |
| Glomerular number                              | 18.32 ± 6.8                    | 16.1 ± 3.8                  | 0.326   |

DM = diabetes mellitus, GN = glomerulonephropathy, PCR = protein creatinine ration, SBP = systolic blood pressure.
aforementioned study may have been underestimated. Allograft kidney biopsy with indication in our protocol had a very low complication rate. Compared to another study on protocol allograft kidney biopsy, 7 patients (2.7%) experienced severe complications: gross hematuria with obstructive acute renal failure in 6 cases and isolated gross hematuria in 1 case. The complication rate was also more than our study (2.7% vs 2.23%).

Within the past 15 years, the only study on allograft kidney biopsy with ‘‘indication’’ was conducted by Nicholson et al. All of the biopsies were performed for acute kidney injury or to monitor the response to antirejection treatment. Size of biopsy needle (14, 16, or 18 gauge) was not a risk factor for complications. The macroscopic hematuria rate was 8%, which was higher than ours (2.23%) but similar to other previous reports from 15 years ago. Two studies reported the rate of gross hematuria was around 3%, but they were done more than 30 years ago. Therefore, in the current era, our study had the lowest complication rates following allograft kidney biopsy with indication. In the past 30 years, there were 7101 renal biopsies, which is the highest number among medical institutes nationwide. Our hospital also has the 3rd highest number of cases of renal transplantation in the country.

Regardless of the type of biopsy, allograft with ‘‘indication’’ or ‘‘protocol’’ kidney biopsy, our protocol had the lowest complication rates. There are a number of reasons which may explain this excellent outcome. First, allograft kidney biopsy was always performed by experienced nephrologists in our hospital. All biopsies were done with the help of real-time sonography-guidance and automated spring-loaded biopsy device. Second, before allograft kidney biopsy, we normalized blood pressure and coagulation function to the biopsy device. Second, before allograft kidney biopsy, we normalized blood pressure and coagulation function to the biopsy device. Third, we did not routinely collect the serum sodium before and after biopsy. To determine any possible complications of Desmopressin, we recommend that future studies measure serum sodium. However, hyponatremia is seldom reported after administration of 1 dose of Desmopressin. Also, we checked serum sodium if patients complained of nausea or vomiting. But not least, we did not record the path-histological results in this article. Some people may wonder that path-histological findings may be associated with the complications of allograft biopsy. However, pathologists read the allograft kidney biopsies based on ‘‘Banff classification,’’ which was modified in 2013. In other words, it is still evolving and changing and there are no absolutely definite criteria for diagnosis. Thus, we did not record the variables of pathological diagnosis in this article.

CONCLUSION

In the modern era, allograft kidney biopsy with indication is safe with acceptable complication rates. Our meticulous survey of coagulation function, routine use of prophylactic Desmopressin, and sonography guidance to avoid biopsying deep in the medulla or medullar tissue only showed that our allograft indication biopsy protocol had the lowest complication rates compared with previously reported rates.

ACKNOWLEDGMENTS

The authors thank TCVGH-T1057804 from Taichung Veterans General Hospital and Taichung University (Taichung, Taiwan) and TCVGH-1053603B from Taichung Veterans General Hospital for the support.

REFERENCES

1. Cameron JS, Hicks J. The introduction of renal biopsy into nephrology from 1901 to 1961: a paradigm of the forming of nephrology by technology. Am J Nephrol. 1997;17:347–358.
2. Iversen P, Brun C. Aspiration biopsy of the kidney. Am J Med. 1951;11:324–330.
3. Donovan KL, Thomas DM, Wheeler DC, et al. Experience with a new method for percutaneous renal biopsy. Nephrol Dial Transplant. 1991;6:731–733.
4. Yoshimoto M, Fujisawa S, Sudo M. Percutaneous renal biopsy well-visualized by orthogonal ultrasound application using linear scanning. Clin Nephrol Aug. 1988;30:106–110.

5. Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62–73.

6. Tondel C, Vikse BE, Bostad L, et al. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988–2010. Clin J Am Soc Nephrol. 2012;7:1591–1597.

7. Wilczek HE. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation. 1990;50:790–797.

8. Franke M, Kramarczyk A, Taylan C, et al. Ultrasound-guided percutaneous renal biopsy in 295 children and adolescents: role of ultrasound and analysis of complications. PLoS One. 2014;9:e114737.

9. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation. 2003;76:969–973.

10. American Diabetes A. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36(Suppl 1):S11–S66.

11. Verdecchia P, Angeli F. [The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready]. Rev Esp Cardiol. 2003;56:843–847.

12. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.

13. Schwarz A, Gwinner W, Hess M, et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transpl. 2005;5:1992–1996.

14. Koo JY, Kadonaga JN, Wintroub BV, et al. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1992;26 (5 Pt 2):836–840.

15. Fereira LC, Karras A, Martinez F, et al. Complications of protocol renal biopsy. Transplantation. 2004;77:1475–1476.

16. Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int. 2000;58:390–395.

17. Waltzer WC, Miller F, Arnold A, et al. Value of percutaneous core needle biopsy in the differential diagnosis of renal transplant dysfunction. J Urol. 1987;137:1117–1121.

18. Pillay VK, Kurtzman NA. Percutaneous biopsy of the transplanted kidney. JAMA. 1973;226:1561–1562.

19. Buselmeier TJ, Schauer RM, Mauer SM, et al. A simplified method of percutaneous allograft biopsy. Nephron. 1976;16:318–321.

20. Nagar D, Wathen RL. An improved method for renal allograft biopsy. Kidney Int. 1979;16:519–521.

21. Horowitz MD, Russell E, Ahtbol C, et al. Massive hematuria following percutaneous biopsy of renal allograft. Successful control by selective embolization. Arch Surg. 1984;119:1430–1433.

22. Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol. 1994;73:13–15.

23. Appel GB, Saltzman MJ, King DL, et al. Use of ultrasound for renal allograft biopsy. Kidney Int. 1981;19:471–473.

24. Tilney NL, Strom TB, Vineyard GC, et al. Factors contributing to the declining mortality rate in renal transplantation. N Engl J Med. 1978;299:1321–1325.

25. Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol. 1992;39:90–95.

26. Manno C, Bonifati C, Torres DD, et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011;57:850–855.

27. Haas M. The revised (2013) banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transpl. 2015. doi: 10.1111/ajt.13661. [Epub ahead of print].

28. De Serres SA, Noel R, Cote I, et al. 2013 Banff Criteria for chronic active antibody-mediated rejection: assessment in a real life setting. Am J Transpl. 2015. doi: 10.1111/ajt.13624. [Epub ahead of print].